Literature DB >> 277244

Some aspects of the metabolism of misonidazole.

I R Flockhart, S L Malcolm, T R Marten, C S Parkins, R J Ruane, D Troup.   

Abstract

The metabolism of the 2-nitroimidazole hypoxic cell radiosensitizer, misonidazole, has been studied in patients receiving radiotherapy. Results are presented which show that the compound reaches adequate levels in tumour tissue and that, in animal systems, reduction products of the nitro group may also be present. Ah h.p.l.c method is described which has been used to quantify unchanged misonidazole and its nitroimidazole metabolites.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277244      PMCID: PMC2149433     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  3 in total

1.  Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo.

Authors:  A J Varghese; S Gulyas; J K Mohindra
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

2.  Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.

Authors:  J L Foster; I R Flockhart; S Dische; A Gray; I Lenox-Smith; C E Smithen
Journal:  Br J Cancer       Date:  1975-06       Impact factor: 7.640

3.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

  3 in total
  2 in total

1.  No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.

Authors:  E J Begg; K M Williams; D N Wade; K F O'Shea
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

2.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.